Description: This structure reveals the molecular basis of unprecedented CDK2 selectivity achieved by a novel (4-pyrazolyl)-2-aminopyrimidine scaffold. The co-crystal with Compound 17 demonstrates how structural insights guided selectivity over CDKs 1, 4, 6, 7, and 9, opening a therapeutic window for CCNE1-amplified cancers.